Skip to main content

Table 1 Estimated IC50 doses of breast cell lines treated with EGFR, MEK, and PI3K inhibitors

From: EGFR associated expression profiles vary with breast tumor subtype

Cell Line Gefitinib (μM) Cetuximab (μg/mL) U0126 (uM) LY294002 (uM)
ME16C 0.3 (0.02) >100a 19.7 (0.66) 21.2 (0.63)
HME-CC 0.2 (0.01) >100a 12.7 (0.33) 7.3 (0.17)
SUM102 0.1 (0.002) 2.3 (0.15) 4.3 (0.20) 3.4 (0.10)
SUM149 4.7 (0.14) >100a 21.8 (0.80) 18.4 (0.48)
MCF-7 21.1 (0.29) >100a 17.0 (1.15) 3.9 (0.13)
ZR-75-1 11.1 (0.12) >100a 25.0 (0.74) 2.4 (0.05)
  1. 72 h IC50 doses were calculated for the EGFR inhibitors gefitinib, cetuximab, the MEK1/2 inhibitor U0126, and the PI3K inhibitor LY294002.
  2. Note that the standard errors are presented within ()
  3. aNo achievable IC50 dose with doses up to 100 μg/mL